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Introduction
Cancer is essentially the term that is used to describe a range of diseases characterized by uncontrolled cell proliferation and migration. Unrestrained cell growth results in the development of tumours, which may present themselves as benign or malignant. While benign tumours are characterised by encapsulated structures and a lack of metastatic behaviour, malignant tumours have the ability to invade and metastasize, an event modulated by the cancer cell and associated with an increased chance of morbidity [1] .
Cancer cell growth is a complex process requiring several physiological changes to occur. Amongst these changes is angiogenesis, the proliferation and de novo alignment of new capillaries from pre-existing blood vessels, in order to support the growth of the tumour and its increased demand for oxygen and nutrients [2, 3] . Under regular circumstances, the process of angiogenesis is regulated by the balance of pro-and anti-angiogenic factors, and occurs during normal healing and repair, however, several factors can result in angiogenesis associated diabetic retinopathy, arthritis, macular degeneration and also pro-metastastic tumour cell growth [3] [4] [5] [6] .
The role of angiogenesis in tumour cell growth has been widely investigated previously by numerous researchers, however, Folkman's group [2] were the ones who initially observed the existence of a correlation between angiogenesis and tumour growth, determining that the development of new blood vessels to supply nutrients and oxygen was necessary for the growth of the cancer cell, and in fact be crucial for metastasis via the bloodstream [3, 7] .
In essence, the particular balance of pro-and anti-angiogenic factors regulates the process of angiogenesis. Such factors, which inhibit the angiogenic process, are pigment epithelium-derived factor (PEDF), thrombospondin-1 (TSP-1) and tissue inhibitor of metalloproteinases (TIMPs), whilst growth stimulators include vascular endothelial growth factors (VEGFs) and the matrix metalloproteinases (MMPs) [5, 6, 8] .
Considering that the factors responsible for angiogenesis are sequestered within the extracellular matrix (ECM) and that cell growth occurs as a result of communication with the immediate environment, naturally, the ECM is essential to the process of both cancer cell growth and angiogenesis. The ECM consists of mainly three structures; (1) proteoglycans, (2) structural proteins that are largely composed of collagen I, II and III, and (3) proteins such as fibrillin and fibronectins [9] . In cancer, these components encounter extensive proteolytic degradation as the tumour cell grows and invades, with ECM degradation and vascular leakage both necessary for angiogenesis to occur and is a process which requires several enzymes, importantly matrix MMPs [10, 11] .
As the name suggests, the MMP family of enzymes play an important role in the breakdown of the ECM [10] . Essentially, the MMP family are a group of calcium-and zincdependent enzymes [10, 12] . Excluding MMP-7, MMP-26 and MMP-23, the typical MMP structure is composed of a hemopexin/vitronectin domain connected by a catalytic domain through a linker region [13] . In general, MMPs are produced by tissues as inactive zymogens and require further activation, however, membrane type matrix metalloproteinase-1 (MT1-MMP; also known as MMP-14) does not require additional activation, due to its capacity to be presented on the cell membrane in its active form [14] . This is an integral part of MT1-MMP's functions as it allows it to in turn, activate matrix metalloproteinase-2 (MMP-2) and combined, the co-ordinate actions of these two proteins have been correlated to the malignancy of a wide variety of cancers [15, 16] .
As discussed, the role of MT1-MMP and MMP-2 in cancer is to facilitate the breakdown of the ECM to allow for aberrant tumour growth. In physiologic conditions, an anti-angiogenic compound balances the functions of pro-angiogenic factors, and one such anti-angiogenic factor found in the body is PEDF.
PEDF is a 50 kDa secreted glycoprotein which was initially localized to the human foetal retinal pigment epithelium (RPE), where it was found to be secreted and to inhibit vascular growth in that tissue [17] [18] [19] . Essentially, PEDF has been determined to be the most potent endogenous angiogenic inhibitor in the body with the ability to prohibit neovascularization in the cornea, as well as endothelial cell growth, tumour proliferation and cancer metastasis [17, 20] . Furthermore, PEDF has also been found to promote neuronal survival and cellular differentiation [21, 22] .
Understanding the various functions of PEDF and the MMPs has been the focus of numerous separate studies previously, though little is known about the direct regulatory interactions that may exist between PEDF and MMPs. The MMP degradation of structural collagens in the ECM prior to angiogenesis, which are essential for structural stability and providing the anchoring points for molecules such as growth factors, fibronectins and proteoglycans, is implicated as an important precursor in cancer progression [10] . Conversely, PEDF has demonstrated capacity as an anti-angiogenesis factor and its ability to target only new vessel growth, as well as its neurotrophic properties and widespread availability in various tissues throughout the body, which indicate that it may be of use as a novel target for cancer therapy [23] . PEDF also has binding sites for collagen within its protein structure. This review will investigate the associations between PEDF, MT1-MMP and MMP-2 in angiogenesis and cancer metastasis.
Understanding PEDF and its potential role in cancer therapy
PEDF is a 50 kDa endogenous protein found in the ECM belonging to the serpin (serine protease inhibitor) family, with a heparin-and collagen-binding site in its structure [18, [24] [25] [26] . It is a potent neurotrophic and angiogenesis-inhibiting factor with tumour suppressor properties [27, 28] .
It is within the ECM where PEDF (Table 1) is naturally found that its anti-angiogenic and tumour-suppressing qualities are understood to take place, however, the exact pathways in which PEDF exerts its various functions are yet to be elucidated [19, 29] . Within the ECM, it has been reported that PEDF engages collagen type I (collagen-1) and III, with immediate binding to collagen-1 possible as a result of PEDF's negatively charged surface binding sites attraction for the positively charged domains of collagen-1 [30, 31] . In fact, PEDF's antiangiogenic effect is understood to be the result of its capacity to inhibit endothelial cell growth and migration through its interaction with collagen-1.
As discussed previously, collagen-1 is a critical angiogenic scaffold essential to the development of capillaries. The interactions of PEDF and its collagen-1 binding site was
investigated by in a study [30] which revealed the importance of this structure in PEDF's functions, determining that mutations in the collagen-1-binding site of PEDF are correlated to the increased progression of tumour vasculature, which consequently allows for tumour advancement.
In addition to PEDF's collagen-1 binding site, its anti-angiogenic functions may be the result of its ability to reduce vessel permeability resulting from VEGF stimulation, by modulating receptors on the cell's surface and inducing apoptosis [19, 30] . Interestingly, it has also been suggested that similar to the pro-angiogenic factors such as VEGF and the proteases of the MMP family, PEDF may exert its anti-angiogenic actions on ECM factors, especially collagen I-IV with its highest affinity reserved for collagen-1 [30] [31] [32] .
It is through the ability to prohibit angiogenesis that PEDF's possible anti-tumour effects were initially examined, in osteosarcoma (OS) research especially. Previous research has shown that PEDF expression levels especially concentrated in areas of the growth plate of bone is correlated with a resistance to tumour growth in that same area [21] . Furthermore, in addition to its anti-angiogenic functions, there are other various ways in which PEDF is understood to attain its anti-tumour effects. These include its ability to inhibit tumour cell migration by promoting cell adhesion, its ability to induce cellular apoptosis and its ability to regulate the differentiation of tumour cells [25] . In effect, a decrease in PEDF concentrations has been correlated to an increased chance of metastasis and poor differentiation in prostate cancer [33] .
However, despite the widely reported anti-angiogenic properties of PEDF, when the role of PEDF on choroidal neovascularisation (CNV), endothelial cell migration and vascular tube formation in vivo was evaluated, it was found that PEDF's anti-angiogenic activities were dependent on the concentration dose of protein that was administered [34] . Remarkably, it was found that although PEDF exerted a decrease in neovascularisation at low concentrations (90 µg/ml), a large increase in PEDF concentrations (to 360 µg/ml) paradoxically resulted in the promotion of vascular growth [34] . The study also found that contrary to previous research, PEDF was able to stimulate VEGF and endothelial cells, which led to an increase in vessel formation. However, the results of the study may have been the result of the regulatory interactions between the pro-and anti-angiogenic factors, and consistent with homeostatic regulation, the large increase in PEDF may have stimulated increases in VEGF and vessel growth.
In various types of tumour cells, PEDF has been shown to decrease levels of VEGF [35] [36] [37] [38] . This is in line with increasing understanding of the complex cross-regulatory interactive nature of molecular components of normal tissue and especially tumour micromilieu in the past decade of cell and molecular biological research. However, despite PEDF's potent antiangiogenic and tumour effects, PEDF's exact molecular mechanisms remain to be completely understood [39] . One perhaps enigmatic molecular function of PEDF is its relationship with MT1-MMP and MMP-2.
The regulatory interactions between PEDF, MT1-MMP and MMP-2
As previously discussed, MT1-MMP is a member of the MMP family of proteases which has been implicated in various cancers for its matrix degrading and pro-angiogenic capabilities [16] . In contrast, PEDF is a protein belonging to the serpin family of inhibitors, which exerts various functions, but importantly, has anti-angiogenic and anti-tumour capabilities [28] . There has been extensive research undertaken which focuses on these two proteins individually, and how their functions affect the outcome of a variety of cancers. However, there have been very few studies which have investigated the direct relationship of these two proteins, and those that are currently available only briefly discuss their associations.
Currently, the interaction between PEDF and MT1-MMP was initially reported in a study in which treatment of chondrosarcoma cells with PEDF resulting in the decrease of MT1-MMP concentrations [40] . More recently [41] , in melanoma cells, increased levels of PEDF MMP-2 is a protease which is closely associated with MT1-MMP (and the malignancy of several cancer types) which interestingly, has been found to be closely associated to PEDF, and MMP-2 has been implicated to downregulate PEDF [42] . The interactions between MMP-2 and PEDF were further demonstrated in a more recent study by [43] which identified that PEDF-deficient mice models with pancreatic tumours displayed increased levels of the proteins MMP-2 and/or MMP-9. Therefore, these findings indicate an inverse correlation between PEDF and MMP-2 during hypoxia and pancreatic cancer, which we hypothesize to occur via MT1-MMP and its activation of MMP-2, though further studies are warranted to confirm this hypothesis.
Given that previous research have suggested the role of PEDF in downregulating MT1-MMP, then therefore, as a result of MMP-2's reliance on MT1-MMP for activation (Fig. 1) , PEDF may also possess the ability to control MMP-2 concentrations despite MMP-2's reported ability to downregulate PEDF concentration levels (though this has to be proven in cells). As a result, PEDF's functions may extend to its ability to regulate MT1-MMP and MMP-2, two of the common proteases implicated in metastatic cancer.
Two recent studies have already shown the efficacy due to systemic delivery of PEDF protein or peptides in models of tumours in vivo [25, 44] . In both cases, the effects of the protein were more significant when metastasis was measured rather than growth of the primary tumour. It is almost common knowledge that it is the spread of a cancer that places the life of the patient in jeopardy, as primary tumours are usually resectable or responsive to therapy. This therefore, open up the promising window of opportunity of being able to curb the spread of tumours with PEDF. As hinted to above, the authors speculate that such important molecular players dictating the ability of cancer cells to migrate from one site to another as MMP-2 and MT1-MMP may be under the control of PEDF.
Conclusion
Cancer progression is associated with angiogenesis, cell migration, and metastasis, events which are modulated by members of the MMP family of proteases, including MT1-MMP and MMP-2. In contrast to the roles of the MMPs, the functions of the potent antiangiogenic protein PEDF in cancer are varied, but essentially include its ability to prevent angiogenesis and tumour progression. Although the molecular mechanisms underpinning PEDF's anticancer activities have yet to be completely understood, it has shown its effectiveness against a variety of cancers. The role of PEDF has been investigated by directly focusing on its capacity to prevent cancer cell growth and angiogenesis in vitro and in vivo. We highlight another aspect of PEDF that warrants further studies: PEDF's associations with the critical factors of angiogenesis, MT1-MMP and MMP-2. 
